- Home
- WIX vs VRNA Comparison
WIX vs VRNA Comparison
Compare WIX & VRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WIX
- VRNA
- Stock Information
- Founded
- WIX 2006
- VRNA 2005
- Country
- WIX Israel
- VRNA United Kingdom
- Employees
- WIX N/A
- VRNA N/A
- Industry
- WIX Computer Software: Programming Data Processing
- VRNA Biotechnology: Pharmaceutical Preparations
- Sector
- WIX Technology
- VRNA Health Care
- Exchange
- WIX Nasdaq
- VRNA Nasdaq
- Market Cap
- WIX 9.2B
- VRNA 8.3B
- IPO Year
- WIX 2013
- VRNA 2017
- Fundamental
- Price
- WIX $160.38
- VRNA $90.48
- Analyst Decision
- WIX Strong Buy
- VRNA Strong Buy
- Analyst Count
- WIX 18
- VRNA 9
- Target Price
- WIX $226.94
- VRNA $112.56
- AVG Volume (30 Days)
- WIX 989.4K
- VRNA 1.2M
- Earning Date
- WIX 08-06-2025
- VRNA 08-07-2025
- Dividend Yield
- WIX N/A
- VRNA N/A
- EPS Growth
- WIX 119.71
- VRNA N/A
- EPS
- WIX 2.51
- VRNA N/A
- Revenue
- WIX $1,814,525,000.00
- VRNA $118,535,000.00
- Revenue This Year
- WIX $13.94
- VRNA $891.79
- Revenue Next Year
- WIX $12.71
- VRNA $78.94
- P/E Ratio
- WIX $63.01
- VRNA N/A
- Revenue Growth
- WIX 12.89
- VRNA N/A
- 52 Week Low
- WIX $137.94
- VRNA $14.15
- 52 Week High
- WIX $247.11
- VRNA $99.01
- Technical
- Relative Strength Index (RSI)
- WIX 50.62
- VRNA 56.61
- Support Level
- WIX $155.04
- VRNA $92.88
- Resistance Level
- WIX $161.00
- VRNA $99.01
- Average True Range (ATR)
- WIX 4.38
- VRNA 3.42
- MACD
- WIX 0.81
- VRNA -0.78
- Stochastic Oscillator
- WIX 69.27
- VRNA 25.24
About WIX Wix.com Ltd.
Wix.com is a software-as-a-service content management system platform that allows users to create, customize, and manage websites for themselves, or for clients. Wix is best known for its Wix Editor service for self-creators, but in recent years has invested heavily and introduced its Wix Studio offering for partners, who are agencies and developers. Wix also offers a range of business solutions such as payment services and marketing products.
About VRNA Verona Pharma plc
Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma.